Mr. Collier has spent his career in healthcare, most recently as CEO of Arsenal Medical, from which he retired in 2015. From 1997 to 2010, Mr....
Mr. Collier has spent his career in healthcare, most recently as CEO of Arsenal Medical, from which he retired in 2015. From 1997 to 2010, Mr. Collier was Executive Vice President at Genzyme Corporation, where he was responsible for building and overseeing several of Genzyme’s business units. He also served as President of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson, and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier sits on the boards of Tesaro, Capricor and Transmedics. He is Chairman of the Board of Trustees of Newton-Wellesley Hospital, and a member of the Board of Trustees of Partners HealthCare. He is member of the Grolier Club in New York and the Book Club of California in San Francisco and serves on the board of the Codex Foundation. He earned a BA at Yale University and a JD at the University of Virginia Law School.
Duke Collier joined Genzyme 1997 after having served as an outside lawyer for the company since 1990. He is responsible for managing Genzyme’s cardiovascular, oncology and genetics businesses, as well as its multiple sclerosis program. Before he joined Genzyme, Mr. Collier was president of Vitas Healthcare Corporation, and a partner at the Washington, D.C. law firm Hogan and Hartson. He also served as deputy administrator for the Health Care Financing Administration in Baltimore, M.D., during the Carter administration. Mr. Collier earned a J.D. at the University of Virginia Law School and a B.A. at Yale University.